Biotech vet MacK­ay grabs a $25M A round to back a gene ther­a­py up­start

Af­ter com­plet­ing an 11-year stint as CEO of Organo­gen­e­sis, Ge­off MacK­ay gath­ered a small, ex­pe­ri­enced team to­geth­er and be­gan a glob­al search for new gene ther­a­pies at Avro­Bio. Ear­li­er this year, they land­ed seed fi­nanc­ing from At­las Ven­ture af­ter ze­ro­ing in on the work of a pair of sci­en­tists in Toron­to. And to­day he land­ed a $25 mil­lion A round to get his two lead pro­grams in­to the clin­ic lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA